HOOKIPA Pharma Inc. - Common Stock (HOOK)
0.8700
+0.0195 (2.29%)
NASDAQ · Last Trade: Apr 5th, 12:20 PM EDT

Vera Bradley faces shareholder pressure for underperformance, while acquisitions and restructurings define this week's deal landscape.
Via Benzinga · January 3, 2025

Via Benzinga · October 30, 2024

HOOK stock results show that HOOKIPA Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 9, 2024

HOOKIPA Pharma shares are trading lower by 10.9% during Monday's session. The company announced a 1-for-10 reverse stock split.
Via Benzinga · July 8, 2024

Via Benzinga · June 5, 2024

Via Benzinga · May 21, 2024

Via Benzinga · April 26, 2024

Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns.
Via InvestorPlace · May 16, 2024

HOOK stock results show that HOOKIPA Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024

HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving significant milestones in collaboration and intellectual property.
Via Benzinga · April 24, 2024

Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx.
Via Benzinga · April 15, 2024

HOOK stock results show that HOOKIPA Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 22, 2024

Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved.
Via Benzinga · February 13, 2024

Via Benzinga · February 8, 2024

Via Benzinga · February 1, 2024

HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments.
Via Benzinga · January 29, 2024

Via Benzinga · January 29, 2024

On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc.
Via Benzinga · January 18, 2024

Via Benzinga · December 25, 2023

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
Via Benzinga · December 22, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.37% to 37,218.15 while the NASDAQ rose 0.73% to 14,885.76. The S&P 500 also rose, gaining, 0.50% to 4,721.72.
Via Benzinga · December 21, 2023

Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.
Via Benzinga · December 21, 2023